Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder

JAMA Neurology

Volumn 72, Issue 7, 2015, Pages 756-763

  Ringelstein, Marius ^a   Ayzenberg, Ilya ^b   Harmel, Jens ^a   Lauenstein, Ann Sophie ^c   Lensch, Eckart ^c   Stögbauer, Florian ^d   Hellwig, Kerstin ^b   Ellrichmann, Gisa ^b   Stettner, Mark ^a   Chan, Andrew ^b   Hartung, Hans Peter ^a   Kieseier, Bernd ^a   Gold, Ralf ^b   Aktas, Orhan ^a   Kleiter, Ingo ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

^c DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^d Hospital Osnabrück   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; AQUAPORIN 4 ANTIBODY; AZATHIOPRINE; C REACTIVE PROTEIN; CARBAMAZEPINE; CORTICOSTEROID; GABAPENTIN; INTERLEUKIN 6 RECEPTOR; METHYLPREDNISOLONE; NALOXONE; NALOXONE PLUS OXYCODONE; PARACETAMOL; PREDNISOLONE SODIUM SUCCINATE; PREGABALIN; TETRAHYDROCANNABINOL; TILIDINE; TOCILIZUMAB; MONOCLONAL ANTIBODY;

ADD ON THERAPY; ADULT; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; DISEASE DURATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; FATIGUE; FEMALE; GASTRITIS; HUMAN; INFECTION; LONG TERM CARE; LYMPHOCYTE COUNT; MYELOOPTIC NEUROPATHY; NAUSEA; NEUROPATHIC PAIN; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PAIN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; DRUG ADMINISTRATION; FOLLOW UP; IMMUNOLOGY; MIDDLE AGED; NEUROMYELITIS OPTICA; TIME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEUROMYELITIS OPTICA; RECEPTORS, INTERLEUKIN-6; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84937558591     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2015.0533     Document Type: Article

References (37)

1. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica (Devic's syndrome). Handb Clin Neurol. 2014;122:581-599.
2. Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation. 2012;9:14.
3. Trebst C, Jarius S, Berthele A, et al Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 2014;261(1):1-16.
4. Shimizu J, Hatanaka Y, Hasegawa M, et al. IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology. 2010;75(16):1423-1427.
5. Kleiter I, Hellwig K, Berthele A, et al Neuromyelitis Optica Study Group. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol. 2012;69(2):239-245.
6. Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler. 2012;18(1):113-115.
7. Elsone L, Kitley J, Luppe S, et al. Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK. Mult Scler. 2014;20(11):1533-1540.
8. Huh SY, Kim SH, Hyun JW, et al. Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA Neurol. 2014;71(11):1372-1378.
9. Kitley J, Elsone L, George J, et al. Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. J Neurol Neurosurg Psychiatry. 2013;84(8):918-921.
10. Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol. 2013;70(9):1110-1117.
11. Kitley JL, Leite MI, Matthews LA, Palace J. Use of mitoxantrone in neuromyelitis optica. Arch Neurol. 2011;68(8):1086-1087.
12. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805-815.
13. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202(4):473-477.
14. Uzawa A, Mori M, Arai K, et al. Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler. 2010;16(12):1443-1452.
15. Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci USA. 2011;108(9):3701-3706.
16. Hashizume M, Tan SL, Takano J, et al. Tocilizumab, a humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis: molecular and cellular mechanistic insights [published online August 6, 2014]. Int Rev Immunol.
17. Kieseier BC, Stüve O, Dehmel T, et al. Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol. 2013;70(3):390-393.
18. Ayzenberg I, Kleiter I, Schröder A, et al. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol. 2013;70(3):394-397.
19. Araki M, Aranami T, Matsuoka T, Nakamura M, Miyake S, Yamamura T. Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol. 2013;23(4):827-831.
20. Araki M, Matsuoka T, Miyamoto K, et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology. 2014;82(15):1302-1306.
21. Lauenstein AS, Stettner M, Kieseier BC, Lensch E. Treating neuromyelitis optica with the interleukin-6 receptor antagonist tocilizumab. BMJ Case Rep. 2014:bcr2013202939. doi:10.1136/bcr-2013-202939.
22. Rose-John S, Gold R. Devic disease: translational medicine at work. Neurology. 2014;82(15):1294-1295.
23. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485-1489.
24. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 1983;33(11):1444-1452.
25. Jarius S, Probst C, Borowski K, et al. Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. J Neurol Sci. 2010;291(1-2):52-56.
26. Van Wagoner NJ, Benveniste EN. Interleukin-6 expression and regulation in astrocytes. J Neuroimmunol. 1999;100(1-2):124-139.
27. Kaplin AI, Deshpande DM, Scott E, et al. IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis. J Clin Invest. 2005;115(10):2731-2741.
28. Zhang H, Bennett JL, Verkman AS. Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms. Ann Neurol. 2011;70(6):943-954.
29. Bennett JL, Lam C, Kalluri SR, et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol. 2009;66(5):617-629.
30. Jarius S, Aboul-Enein F, Waters P, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain. 2008;131(pt 11):3072-3080.
31. Kanamori Y, Nakashima I, Takai Y, et al. Pain in neuromyelitis optica and its effect on quality of life: a cross-sectional study. Neurology. 2011;77(7):652-658.
32. Qian P, Lancia S, Alvarez E, Klawiter EC, Cross AH, Naismith RT. Association of neuromyelitis optica with severe and intractable pain. Arch Neurol. 2012;69(11):1482-1487.
33. Bradl M, Kanamori Y, Nakashima I, et al. Pain in neuromyelitis optica: prevalence, pathogenesis and therapy. Nat Rev Neurol. 2014;10(9):529-536.
34. Uzawa A, Mori M, Kuwabara S. Cytokines and chemokines in neuromyelitis optica: pathogenetic and therapeutic implications. Brain Pathol.2014;24(1):67-73.
35. Ohtori S, Miyagi M, Eguchi Y, et al. Efficacy of epidural administration of anti-interleukin-6 receptor antibody onto spinal nerve for treatment of sciatica. Eur Spine J. 2012;21(10):2079-2084.
36. Smolen JS, Beaulieu A, Rubbert-Roth A, et al OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987-997.
37. Besada E. Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review. Patient Prefer Adherence. 2014;8:1051-1059.